Skip to main content

Table 2 Response to FTM treatment according to time of TMZ failure for the entire population

From: A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy

Variable B0 B1 B2 B3 All
Number of pts 20 50 45 48 163
Response to FTM % (N)
 CR 0 2 (1) 2.2 (1) 2.1 (1) 1.8 (3)
 PR 15 (3) 10 (5) 15.6 (7) 16.7 (8) 14.1 (23)
 SD 30 (6) 24 (12) 24.4 (11) 47.9 (23) 31.9 (52)
 DP 55 (11) 64 (32) 57.8 (26) 33.3 (16) 52.1 (85)
Disease Control % (N)
 Yes 45 (9) 36 (18) 42.2(19) 66.7 (32) 47.8 (78)
PFS-6 m % (N)
 Yes 25 (5) 28 (14) 31.1 (14) 43.8 (21) 33.1 (54)
OS-1y % (N)      
 Yes 25 (5) 24 (12) 28.9 (13) 31.3 (15) 27.6 (45)
Time to DP after FTM
 Days median (range) 111
(83 - 182)
91
(43 - 156)
104
(58 - 190)
139
(62 - 252)
104
(58 - 193)
  1. CR: complete response; PR: partial response; SD: stable disease; DP: disease progression; PSF-6 m: progression free survival at 6 months; OS-1y: overall survival at 1 year; FTM: fotemustine. B0: patients failing after radiotherapy completion and before starting adjuvant TMZ; B1: patients failing during the first 6 months of adjuvant TMZ; B2: patients who failed after more than 6 months of therapy; B3: patients who experienced tumor recurrence after a treatment-free interval.